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Ultrahigh performance liquid chromatography-electrospray ionization-tandem mass spectrometry (UPLC-
ESI-MS/MS) provides a high-speed method to screen a large number of samples for small molecules with
specific properties. In this study, UPLC-ESI-MS/MS with multiple reaction monitoring (MRM) was employed
to screen urinary phospholipid (PL) content for biomarkers of prostate cancer. From lists of urinary PLs
structurally identified using nanoflow LC-ESI-MS/MS, 52 PL species were selected for quantitative analysis
in urine samples between 22 cancer-free urologic patients as controls and 45 prostate cancer patients. Statistical
treatment of data by receiver operating characteristic (ROC) analysis yielded 14 PL species that differed
significantly in relative concentrations (area under curve (AUC) > 0.8) between the two groups. Among PLs
present at higher levels in prostate cancer urine, phosphatidylcholines (PCs) and phosphatidylinositols (PIs)
constituted the major head group PLs (3 PCs and 7 PIs). For technical reasons, PL species of low abundance
may be underrepresented in data from UPLC-ESI-MS/MS performed in MRM mode. However, the proposed
method enables the rapid screening of large numbers of plasma or urine samples in the search for biomarkers
of human disease.
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Introduction
Prostate cancer is the most common cancer among men in
the developed world, and tends to develop in men over the
age of fifty. Rates of prostate cancer detection vary world-
wide.1,2 Prostate cancer diagnosis is based on symptoms,
tissue biopsy, and measurements of prostate-specific antigen
(PSA) in blood. While the PSA test is the most common
screening implement for the disease, a reliable method is
still needed, since the PSA test is in some case unreliable.3
An ideal biomarker for prostate cancer would be a mole-
cular species involved in the early steps of carcinogenesis.
Use of mass spectrometry (MS) in the proteomic or meta-
bolomic analysis of human urine has yielded annexin A34
and basic human urinary arginine amidase5 as protein
markers, and sarcosine6 as a metabolic marker of the disease.
Lipids have attracted interest in the search for biomarkers
because of their structural diversity and complexity and
involvement in hormonal signaling, particularly through the
regulation of membrane receptors that mediate interactions
between cells. Lipid composition largely governs the struc-
ture and function of cell membranes.7 Precisely because
lipids are structurally complex and diverse, a lipidomics
study must begin with a comprehensive characterization of
the lipid content of the material of interest. Useful techno-
logies for lipid analysis include nuclear magnetic resonance
(NMR) spectroscopy,8,9 Raman spectroscopy,10 gas chromato-
graphy-mass spectrometry (GC-MS),11,12 and electrospray
ionization-mass spectrometry (ESI-MS).13,14 However, liquid
chromatography-ESI-tandem mass spectrometry (LC-ESI-
MS/MS) in particular facilitates lipidomic analysis in
separating complicated lipid mixtures with subsequent soft
ionization of lipid molecules without preliminary modi-
fication and in deriving structural information from frag-
ments of target ions.15-17 Several classes of mammalian lipids
have been examined as biological indicators for various di-
seases, including Alzheimer’s disease,18 pancreatic cancer,19
mitochondrial dysfunction,20 breast cancer,21 coronary artery
disease (CAD),22 and prostate cancer.23 Urinary PLs between
prostate cancer patients and healthy controls were examined
by using nLC-ESI-MS/MS in our earlier study,24 however
due to the relatively low speed it was limited to analyze
small number of samples.
This study investigated potential urinary phospholipid bio-
markers of prostate cancer using ultrahigh performance LC-
ESI-MS/MS (UPLC-ESI-MS/MS) with statistical analysis.
Initially, 52 urinary PL species, found greater than the limit
of quantitation of method applied in present study and
identified by structural determination using nanoflow LC/
ESI-MS/MS in the previous study25 were selected for the
high speed screening of a large number of urine samples
with prostate cancer. The current study was expanded to
urologic patient groups (22 cancer-free urologic patients
including benign prostate hyperplasia as controls in com-
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parison to 45 prostate cancer patients) and quantitation was
made by using multiple reaction monitoring (MRM) of
fragment ions using UPLC/ESI-MS/MS. Quantitative data
for potential PL biomarkers were screened for significance
using receiver operating characteristic (ROC) analysis, a
widely used biomarker discovery tool26-29 that measures
selectivity and sensitivity simultaneously.
Experimental
Materials and Reagents. Twenty phospholipid standards
(12:0-LPC (lysophosphatidylcholine), 16:0-LPC, 14:0-LPE
(lysophosphatidyl ethanolamine), 18:0-LPE, 12:0/12:0-PC
(phosphatidylcholine), 16:0/14:0-PC, 16:0/16:0-PC, 18:0/
18:1-PC, 20:0/20:0-PC, 12:0/12:0-PE, 16:0/16:0-PE, 18:0/
18:0-PE, 18:0-LPA (lysophosphatidic acid), 18:0-LPG (lyso-
phosphatidylglycerol), 18:0-LPS (lysophosphatidyl-serine),
18:1-LPI (lysophosphatidylinositol), 16:0/16:0-PA, 14:0/14:0-
PG, 18:0/18:0-PS and 16:0/18:2-PI) were purchased from
Avanti Polar Lipids (Alabaster, AL, USA) to establish optimal
separation conditions, cone voltage, and MS collision energy
for each different PL head group in UPLC-ESI-MS-MS
analysis. Formic acid, ammonium hydroxide, and chloro-
form were all MS grade and were obtained from Sigma (St.
Louis, MO, USA). Solvents used for UPLC-ESI-MS experi-
ments (water, acetonitrile, methanol, and isopropanol) were
all HPLC grade and were purchased from Avantor Perfor-
mance Materials (Phillipsburg, NJ, USA).
Urine Samples and Lipid Extraction. Sixty-seven patients
were selected from the Institutional Review Board (IRB)
database. Urine samples were collected from 22 cancer-free
urologic patients with conditions that included benign
prostate hyperplasia as controls and from 45 prostate cancer
patients who visited Severance Hospital, Yonsei University
College of Medicine (Seoul, Korea) from 2011 to 2012. The
cancer patient urine samples were collected just before
prostatectomy, and the control samples were obtained after
fasting. Data for controls and patients (Table 1) show
significant differences between the two groups in PSA level.
Subjects in the control group were overweight (body mass
index (BMI) 25.0-29.9) and cancer patients were of normal
or subnormal body weight (BMI < 25). Urine samples were
stored at −20 °C immediately after collection until lipid
extraction.
Lipids were extracted from human urine as previously
described30 with modifications. Briefly, 5 mL of each urine
sample was transferred to a 15 mL centrifuge tube, and the
tube was wrapped with MilliWrap from Merck Millipore
(Billerica, MA, USA). Tubes thus prepared were placed
under liquid nitrogen for rapid freezing and lyophilized for
12 hours in a vacuum centrifuge from Ilshin Biobase Co.
(Yangju, Korea). Recovered sediment was reconstituted with
4.5 mL of CHCl3:CH3OH (2:1) solution containing spiked
phospholipids, 13:0/13:0-PC and 15:0/15:0-PG, as internal
standards for positive and negative ion modes in MS analysis,
respectively, at final concentrations of 200 fmol/µL. Then,
900 µL of MS-grade water was added and the mixture was
vortexed thoroughly. The mixture was centrifuged at 2500
rpm for 10 minutes and the lower organic layer was trans-
ferred to a new centrifuge tube and vacuum centrifuged for
drying. The recovered lipids were reconstituted with
CH3OH:CH3CN (9:1) solution to a final concentration of
100 µg/µL and stored at 4°C for the UPLC-ESI-MS/MS
experiments.
UPLC-ESI-MS/MS. An ultrahigh performance liquid
chromatography (UPLC) system coupled to a Xevo TQ mass
spectrometer from Waters (Milford, MA, USA) was used to
separate the complex mixture of extracted lipids, and the
components were quantified using an analytical column,
Xbridge C18 (3.5 µm, 2.1 × 50 mm) from Waters. From each
urinary lipid extract, 1 µL was injected through an auto-
sampler and separation was allowed to proceed at a fixed
flow rate of 0.4 mL/min. A binary gradient elution was
applied, with water for solvent A and 10/30/60 (v/v/v)
methanol/acetonitrile/isopropanol for solvent B. Each mobile
phase was supplemented, with 0.1% formic acid for positive
ion mode and 0.05% ammonium hydroxide for negative ion
mode to enhance ionization of PLs during MS. Quanti-
fication was made through the multiple reaction monitoring
(MRM) component of MS/MS. All analyses described
above, including lipid extraction, were repeated three times.
Capillary voltage was set at 3.0 kV. Cone voltage, collision
energy, and other experimental conditions for MRM analysis
were adjusted for each PL depending on the type of polar
head group (see Table 2). In a previous study,31 class-specific
daughter ions were used as quantifier ions for MRM; how-
ever, acyl chain-specific fragment ions were denoted as
daughter ions for each class to distinguish the composition
Table 1. Demographic features of control subjects and patients with prostate cancer
Control (n=20)
Patient
p-value
(p vs c)Overall (n=43)
Gleason Score
6 7 8 9
(n=10) (n=27) (n=2) (n=4)
Age (yrs) 60.5 ± 15.2 64.6 ± 8.3 63.0 ± 7.2 63.7 ± 8.9 72.5 ± 2.1 68.8 ± 6.1 0.269
Height (cm) 168.8 ± 6.6 167.5 ± 5.3 165.6 ± 5.7 168.5 ± 5.4 166.5 ± 7.8 166.7 ± 2.6 0.446
Weight (kg) 68.3 ± 8.2 68.2 ± 7.3 65.7 ± 5.6 69.5 ± 8.1 61.0 ± 5.7 70.0 ± 3.6 0.963
BMI 27.9 ± 6.3 24.3 ± 2.0 24.0 ± 1.5 24.5 ± 2.2 22.0 ± 0.0 25.2 ± 1.4 0.021
PSA 3.3 ± 6.8* 9.0 ± 5.7 9.2 ± 3.1 8.6 ± 4.6 9.6 ± 0.0 9.7 ± 15.4 0.003
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of the two acyl chains. The peak area of each species was
calculated by MassLynx from Waters, and the peak area
ratio of target species was calculated relative to the area of
an internal standard at each ion mode (13:0/13:0-PC for
positive ion and 15:0/15:0-PG for negative ion mode).
Statistical Methods. Specificities and sensitivities for
ROC curve generation, as well as precision and F-measure
generation values, were calculated by establishing diverse
threshold values using Microsoft Excel. Student’s t-test was
performed for each PL candidate using Minitab 15
(www.minitab.co.kr). Final selection of PL markers from
screening was based on the following threshold criteria:
more than a 3-fold difference between control and patient
groups, p-value less than 0.01, and area under the curve
(AUC) of more than 0.8.
Results and Discussion
Figure 1 shows the base peak chromatograms of a) twelve
PL standards and b) urinary lipid extracts of a cancer-free
control (hereafter as control) and a prostate cancer patient
sample (hereafter patient sample) with IS added (13:0/13:0-
PC) in positive ion mode. Figure 1(a) demonstrates that PL
standards can be separated in less than 8 minutes by UPLC-
ESI-MS with sufficient resolution to separate LPL regioiso-
mers: peaks 1a and 1b in the enlarged chromatogram re-
present lyso/12:0-PC and 12:0/lyso-PC, respectively. During
each UPLC-ESI-MS/MS run of urinary extract, 52 target PL
species were quantitatively analyzed by calculating the peak
area of each daughter ion (quantifier ion) obtained by the
MRM method. These 52 target PL molecules were selected
for analysis from among the 85 species of urinary PLs that
we previously identified and characterized using nLC-ESI-
MS/MS.25 The quantifier ions used for each PL group
selected were the fragment ions obtained by loss of an acyl
chain (sn-1 for diacyl PLs) from each parent ion as [M+H-
RCOOH]+ for the LPC, PC, PE, and LPE groups, and the
free carboxylate ion, [RCOO]−, for PS, PI, LPS, PG, PA, and
LPA groups. The m/z values of the precursor ion and the
corresponding daughter ion of each PL species are listed in
Table 2 along with their corresponding molecular chain
structures. For the head group of each PL species, cone
voltage and collision voltage were separately controlled. For
Table 2. List of targeted PL groups and the corresponding MS/MS conditions adjusted for the type of head group. Molecular species
examined in MRM mode during UPLC-ESI-MS/MS and their characteristic m/z values for precursor ions and quantifier ions are listed
Cone/
Collision
Voltage (V)
Type of 
precursor/
quantifier ions
Molecular Species (m/z of precursor/quantifier ions)
LPC (3) 35 / 30
[M+H]+/
[M+H-RCOOH]+
14:0/lyso (468/240), lyso/18:2 (520/240), 16:0/lyso (496/240)
LPE (4) 25 / 20 lyso/20:4 (502/224), 20:4/lyso (454/224), 
16:0/lyso (480/224), 18:1/lyso (482/224)
PC (12) 35 / 30 16:0/22:6 (806/550), 16:0/20:4 (782/526), 18:2/18:2 (782/502), 16:0/18:2 (758/502), 18:0/20:5 
(808/524), 18:1/18:2 (784/502), 16:0/16:0 (734/478), 16:0/18:1 (760/504), 18:0/20:4 (810/526), 
18:1/18:1 (786/504), 18:0/18:2 (786/502), 18:0/18:1 (788/504)
PE (10) 25 / 20 16:0/22:6 (764/508), 16:0/20:4 (740/484), 18:1/20:4 (766/484), 16:0/18:2 (716/460), 18:1/18:2 
(742/460), 16:0/18:1 (718/462), 18:1/18:1 (744/462), 18:0/18:2 (744/460), 18:0/20:4 (768/484), 
18:0/18:1 (746/462)
LPS (1) 35 / 30
[M-H]−/
[RCOO]−
lyso/18:0 (524/283)
LPA (2) 42 / 24 lyso/16:0 (409/255), lyso/18:0 (437/283)
PS (5) 53 / 45 16:0/18:1 (760/255), 18:0/20:4 (810/283), 18:1/18:1 (786/281), 18:0/18:2 (786/283), 18:0/18:1 
(788/283)
PI (11) 75 / 45 16:0/20:4 (857/255), 16:0/20:3 (859/255), 18:0/20:4 (885/283), 16:0/16:0 (809/255), 16:0/18:1 
(835/255), 18:1/16:0 (835/281), 18:1/18:1 (861/281), 18:0/18:2 (861/283), 18:0/20:3 (887/283), 
16:0/18:0 (837/255), 18:0/18:1 (863/283)
PG (2) 57 / 46 18:2/22:6 (817/279), 18:1/22:6 (819/281)
PA (2) 42 / 36 16:0/16:0 (647/255), 18:0/18:2 (699/283)
Figure 1. Base peak chromatograms (BPCs) of (a) 12 PL standards
and (b) lipids extracted from urine samples of a cancer-free control
patient and a prostate cancer patient using nLC-ESI-MS/MS with
an IS (13:0/13:0-PC). Standard PLs were 1. 12:0-LPC (1a for lyso/
12:0-PC and 1b for 12:0/lyso-PC), 2. 14:0-LPE, 3. 16:0-LPC, 4.
18:0-LPE, 5. 12:0/12:0-PC, 6. 12:0/12:0-PE, 7. 14:0/16:0-PC, 8.
16:0/16:0-PC. 9. 16:0/16:0-PE, 10. 18:0/18:0-PC, 11. 18:0/18:0-PE,
and 12. 20:0/20:0-PC.
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all 52 PL species, triplicate measurements were made for
each urinary extract sample. Figure 2 shows an example of
average relative peak area ratio (vs. IS) of 16:0/18:0-PI plott-
ed for all control and cancer patient samples. Each patient
sample was plotted two different ways: one for overall
Gleason Score and the other for individual Scores. Gleason
score is a system of grading ranging from 0 to 10 that sup-
port the prognosis of a person with prostate cancer with the
greater score meaning the worse tumor prognosis. Basically,
it is the sum of two individual numbers assigning ‘primary
grade’ and ‘secondary grade’ of the tumor observed. Figure
2 shows a very broad distribution of the relative abundances
of 16:0/18:0-PI species among cancer patients and a distri-
bution among controls that is comparatively narrow. The
coefficient of variation (CV) in triplicate measurements of
each species was less than 5% (data not shown for each).
After calculating the average peak area ratio, Grubb’s test,
which is to find and eliminate possible outliers in a univariate
data from a population conforming to the normal distribution,
was applied to eliminate outliers. This revealed a significant
difference within each control and patient group, resulting in
the exclusion of two control samples and two patient
samples from the original dataset prior to calculation of the
abundance ratios (patient over control). The average relative
peak area of each urinary PL for the control group (n=20)
and the prostate cancer patient group (n=43) are listed in
Table S1 of Supporting Information. Data for the patient
group are expressed by overall and individual Gleason Scores
(G=6 (n=10), 7 (n=27), 8 (n=2), and 9 (n=4)). Among the 52
species examined in this study, 32 molecular species differed
significantly in relative peak area (greater than three-fold)
between control and patient groups. To evaluate correlations
with the presence or progression of prostate cancer, stati-
stical calculations were applied for the first 32 PL species
screened. A contingency table was established for each
species to calculate the following parameters: sensitivity,
selectivity (or specificity), precision, balanced accuracy, F-
measure, and area under the ROC curve (AUC). To calculate
statistical parameters for each PL species screened, 17 thre-
shold values (or classifiers) of peak area ratio were selected;
these thresholds were established at the medians and quartiles
of each distribution (Figure 2). The numbers of samples
within or out of each threshold value were counted to cal-
culate true positive, false positive, false negative, and true
negative rates, so as to calculate sensitivity (rate of declaring
true positive values as true), selectivity (rate of declaring
false positive as false), precision (rate of true counts to total
counts that were declared as true), balanced accuracy ((sensi-
tivity + selectivity)/2), and F-measure (harmonic mean of
precision and sensitivity). The ROC curve in Figure 3 was
generated by plotting sensitivity vs. (1-selectivity) calculated
at all 17 threshold values for 16:0/18:0-PI (see Figure 2).
The dotted line represents the perfect model. The area under
the ROC curve (AUC) was calculated for each species.
From these calculations, 14 PL species were selected from
the 32 species based on the following criteria: AUC > 0.800,
p/c ratio > 3.00, p-value < 0.01, sensitivity > 0.500 and
balanced accuracy > 0.700. The final 14 PL species were
divided into two classes (nine species for AUC > 0.900 and
five species for 0.800 < AUC < 0.900; Table 3). Sensitivity
and selectivity values shown for each species listed in Table
3 are the values yielding the maximum value of a sum (sensi-
tivity + selectivity). In an earlier study, we demonstrated the
use of nLC-ESI-MS/MS in a semi-quantitative analysis of
urinary PL species from 9 prostate cancer patients and 10
healthy control subjects.24 That study identified 10 potential
prostate cancer biomarkers, i.e., PL species showing greater
than 3-fold difference in relative levels between patients and
controls. In this study, several experimental conditions have
been changed. These include the number of patient samples
(n=43 for the present work vs. 9 for the previous one),
Figure 2. Plot of peak area ratio (vs. IS) of 16:0/18:0-PI from
controls (n=20) and patients (n=43). Data for patient group are
plotted by overall and by individual Gleason Scores (G=6, 7, 8,
and 9).
Figure 3. ROC curve of 16:0/18:1-PI species showing the
correlation between sensitivity and 1-selectivity calculated at 17
threshold points. The dotted line represents the perfect model.
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sample origin, quantification method (quantifier ion obtain-
ed in MRM mode vs. peak area measurement of precursor
ion from extracted ion chromatogram), MS instrument type
(triple quadrupole vs. ion trap), injected amount of PL
extracts (100/100 µg vs. 15/5 µg for positive/negative ion
modes), and LC columns and flow rate (0.4 mL/min vs. 300
nL/min) for ESI. In particular, the ionization efficiencies of
PL in two ESI-MS experiments run at different flow rates
may differ significantly, and thus, low abundance PL species
counted as candidates in the previous run were not detected
in the present study. Moreover, the present study compared
the difference between prostate cancer patient samples and
cancer-free urologic patients with benign prostate hyperplasia,
while the former study focused on the difference in prostate
cancer patients from healthy controls. Among the 10 selected
PL species (excluding LPE and LPS) listed in Table 3, three
PL species (18:1/18:1-PC, 18:0/18:1-PC, and 18:0/20:4-PI)
were detected as high abundance species with significantly
higher levels in cancer patient samples in both experiments.
The p/c ratio for each species calculated was 6.69 ± 7.66
from UPLC-ESI-MS/MS (5.12 ± 2.09 from nLC-ESI-MS)
for 18:1/18:1-PC, 7.49 ± 11.47 (3.26 ± 1.76) for 18:0/18:1-
PC, and 3.17 ± 3.15 (5.97 ± 4.82) for 18:0/20:4-PI. While
two other PL species (16:0/18:2-PC and 16:0/18:1-PI) show-
ed significant increases (p/c > 4) in both experiments, these
were not included in Table 3 since they did not meet the
statistical thresholds applied in the present study.
Principal component analysis (PCA) was applied to the 14
selected species in Table 3, and the resulting plots are shown
in Figure 4. The scores plot in the left of Figure 4 shows that
points for cancer-free patient samples (filled circles) cluster
at the upper left of the plot while the points (open circles) for
the cancer patient group are widely scattered, indicating that
relative amounts of these 14 species vary widely within the
cancer group. The loading plot at the right side of Figure 4
shows the narrow distribution of 14 selected species (see x-
and y-axis scales in comparison to those of the scores plot),
indicating that the relative amounts of these species are
significantly higher in cancer patients than in cancer-free
controls.
Conclusion
This study demonstrated the utility of UPLC-ESI-MS/MS
in the quantitative analysis of urinary phospholipids in an
effort to develop biomarkers for prostate cancer. Complex
urinary phospholipids were separated at high speed (10 min
or less) by UPLC. Statistical analysis revealed significant
quantitative differences in PL content between urine samples
from prostate cancer patients and control samples from
cancer-free urologic patients. Based on this analysis of 20
control and 43 prostate cancer samples, patients with pro-
state cancer may excrete several PL species at significantly
higher concentrations than do subjects of comparable age
Table 3. List of potential PL biomarkers statistically selected by the following criteria: ratio (patient/control) > 3.00, p-value < 0.01,
sensitivity > 0.500, balanced accuracy > 0.700, and AUC > 0.900 (for first nine species) and AUC > 0.800 (for the last five species)
Lipid Species Ratio (P/C) p-value Sens. Selec. Prec.
Balanced 
Accuracy
Inform. MCC F-measure AUC
PC1 18:1/18:1-PC 6.69 ± 7.66 < 0.001 0.651 1.000 1.000 0.826 0.651 0.610 0.789 0.939 
PC2 16:0/16:0-PC 5.52 ± 6.71 < 0.001 0.698 0.950 0.968 0.824 0.648 0.603 0.811 0.931 
PC3 18:0/18:1-PC 7.49 ± 11.44 < 0.001 0.674 0.900 0.935 0.787 0.574 0.535 0.784 0.917 
PI1 16:0/18:0-PI 14.23 ± 19.85 < 0.001 0.605 1.000 1.000 0.802 0.605 0.572 0.754 0.946 
PI2 16:0/20:3-PI 7.40 ± 9.04 < 0.001 0.558 1.000 1.000 0.779 0.558 0.535 0.716 0.938 
PI3 18:0/18:2-PI 6.19 ± 8.27 < 0.001 0.674 0.900 0.935 0.787 0.574 0.535 0.784 0.920 
PI4 18:0/20:3-PI 5.96 ±7.12 < 0.001 0.698 0.950 0.968 0.824 0.864 0.603 0.811 0.919 
PI5 16:0/20:4-PI 4.37 ± 6.64 < 0.001 0.535 0.950 0.958 0.742 0.485 0.465 0.687 0.912 
PI6 18:0/18:1-PI 7.60 ± 9.89 < 0.001 0.698 0.950 0.968 0.824 0.648 0.603 0.811 0.901 
PI7 18:0/20:4-PI 3.17 ± 3.15 < 0.001 0.698 0.750 0.857 0.724 0.448 0.419 0.769 0.877 
PE1 18:0/18:2-PE 3.47 ± 3.81 < 0.001 0.651 0.850 0.903 0.751 0.501 0.467 0.757 0.866 
LPE1 16:0/lyso-PE 4.48 ± 6.92 < 0.001 0.674 0.900 0.935 0.787 0.574 0.535 0.784 0.856 
LPE2 18:1/lyso-PE 5.03 ± 7.96 < 0.001 0.651 0.850 0.903 0.751 0.501 0.467 0.757 0.849 
LPS1 lyso/18:0-PS 5.35 ± 12.14 0.007 0.628 0.800 0.871 0.714 0.428 0.398 0.730 0.800 
Figure 4. Principal component analysis (PCA) plots for the 14
selected PL species listed in Table 3. The narrow distribution of
these 14 species in the loading plot at the right side (compare
scales of the two axes) indicates that they are increased in the
patient group.
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who do not have prostate cancer but with benign prostate
hyperplasia. Among the 14 PL species detected at highest
levels (AUC > 0.800) in prostate cancer, three PCs and
seven PIs constitute major head groups. Increased level of
PC in patients with prostate cancer is consistent with
published data on the relative levels of PCs in samples of
patients’ plasma23 and of PC in high-grade prostate cancer
tissues.32 In addition, 18:1/18:1-PC, 18:0/18:1-PC, and 18:0/
20:4-PI were among the selected species found in our
previous study to be significantly increased in patients with
prostate cancer compared to healthy controls,24 although
experimental conditions in that study differed from those in
the present one (see above). 
A limitation of the present study is the difficulty of detect-
ing low-abundance PL species and some head groups (PS
and PA) which are not favorably ionized if there is spectral
congestion under the relatively high feeding flow rate used
in UPLC-ESI-MS/MS compared with nLC-ESI-MS/MS.
Given the small number of samples in this study, the validity
of the selected PL species as biomarkers is uncertain. How-
ever, the current study demonstrates the capability of UPLC-
ESI-MS/MS to systematically screen large numbers of samples
for molecular species with selected properties. These same
features may be applied in the search for biomarkers of other
significant adult diseases, including breast cancer and athero-
sclerosis.
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